BAX vs. PODD, TFX, RMD, GMED, DXCM, BDX, WST, SWAV, SOLV, and PEN
Should you be buying Baxter International stock or one of its competitors? The main competitors of Baxter International include Insulet (PODD), Teleflex (TFX), ResMed (RMD), Globus Medical (GMED), DexCom (DXCM), Becton, Dickinson and Company (BDX), West Pharmaceutical Services (WST), Shockwave Medical (SWAV), Solventum (SOLV), and Penumbra (PEN). These companies are all part of the "surgical & medical instruments" industry.
Baxter International (NYSE:BAX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Baxter International has higher revenue and earnings than Insulet. Baxter International is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Baxter International has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
In the previous week, Baxter International had 24 more articles in the media than Insulet. MarketBeat recorded 30 mentions for Baxter International and 6 mentions for Insulet. Insulet's average media sentiment score of 1.15 beat Baxter International's score of 0.50 indicating that Insulet is being referred to more favorably in the news media.
Baxter International has a net margin of 17.77% compared to Insulet's net margin of 12.16%. Insulet's return on equity of 32.19% beat Baxter International's return on equity.
Baxter International received 20 more outperform votes than Insulet when rated by MarketBeat users. Likewise, 66.30% of users gave Baxter International an outperform vote while only 65.98% of users gave Insulet an outperform vote.
Baxter International currently has a consensus target price of $46.30, indicating a potential upside of 25.44%. Insulet has a consensus target price of $243.21, indicating a potential upside of 40.25%. Given Insulet's stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than Baxter International.
90.2% of Baxter International shares are owned by institutional investors. 0.2% of Baxter International shares are owned by company insiders. Comparatively, 0.5% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Insulet beats Baxter International on 10 of the 18 factors compared between the two stocks.
Get Baxter International News Delivered to You Automatically
Sign up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baxter International Competitors List
Related Companies and Tools
